| Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients A Vijenthira, IY Gong, TA Fox, S Booth, G Cook, B Fattizzo, F Martín-Moro, ... Blood, The Journal of the American Society of Hematology 136 (25), 2881-2892, 2020 | 600 | 2020 |
| COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus L Scarfò, T Chatzikonstantinou, GM Rigolin, G Quaresmini, M Motta, ... Leukemia 34 (9), 2354-2363, 2020 | 260 | 2020 |
| COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study T Chatzikonstantinou, A Kapetanakis, L Scarfò, G Karakatsoulis, D Allsup, ... Leukemia 35 (12), 3444-3454, 2021 | 76 | 2021 |
| Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL A Agathangelidis, A Chatzidimitriou, T Chatzikonstantinou, C Tresoldi, ... Leukemia 36 (8), 1961-1968, 2022 | 44 | 2022 |
| An update in drug-induced thrombotic microangiopathy T Chatzikonstantinou, M Gavriilaki, A Anagnostopoulos, E Gavriilaki Frontiers in Medicine 7, 212, 2020 | 26 | 2020 |
| Endothelial and complement activation as predictors of survival in adult allogeneic hematopoietic cell transplantation E Gavriilaki, I Sakellari, T Chatzikonstantinou, D Mallouri, I Batsis, A Vardi, ... Hemasphere 5 (1), e487, 2021 | 22 | 2021 |
| COVID-19 and chronic lymphocytic leukemia: where we stand now T Chatzikonstantinou, Y Herishanu, E Montserrat, P Ghia, A Cuneo, R Foa, ... The Cancer Journal 27 (4), 328-333, 2021 | 11 | 2021 |
| Biology and treatment of high-risk CLL: significance of complex karyotype T Chatzikonstantinou, C Demosthenous, P Baliakas Frontiers in Oncology 11, 788761, 2021 | 9 | 2021 |
| Real-world data of thrombotic microangiopathy management: The key role of ADAMTS13 activity and complement testing E Gavriilaki, EE Koravou, T Chatziconstantinou, C Kalpadaki, N Printza, ... Thrombosis Update 3, 100043, 2021 | 7 | 2021 |
| Challenges and solutions for collecting and analyzing real world data: the Eric CLL database as an illustrative example A Chatzidimitriou, E Minga, T Chatzikonstantinou, C Moreno, ... Hemasphere 4 (5), e425, 2020 | 6 | 2020 |
| Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study S Chatzileontiadou, E Hatjiharissi, M Angelopoulou, JV Asimakopoulos, ... Frontiers in Oncology 13, 1128994, 2023 | 5 | 2023 |
| Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL D Antic, N Milic, T Chatzikonstantinou, L Scarfò, V Otasevic, N Rajovic, ... Journal of hematology & oncology 15 (1), 116, 2022 | 5 | 2022 |
| Worldwide examination of patients with CLL hospitalized for COVID-19 LE Roeker, L Scarfo, T Chatzikonstantinou, P Abrisqueta, TA Eyre, ... Blood 136, 45-49, 2020 | 5 | 2020 |
| The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL A Visentin, T Chatzikonstantinou, L Scarfò, A Kapetanakis, ... American journal of hematology 98 (12), 1856-1868, 2023 | 4 | 2023 |
| Predictors of transplant-associated thrombotic microangiopathy in patients with overlap or chronic graft-vs-host-disease E Gavriilaki, I Sakellari, T Chatzikonstantinou, Z Bousiou, D Mallouri, ... Transplantation Proceedings 53 (7), 2261-2266, 2021 | 4 | 2021 |
| Plasmic and plasic αre εxcellent predictors of severe ADAMTS13 deficiency in thrombotic microangiopathy patients without secondary causes E Gavriilaki, E Koravou, T Chatziconstantinou, C Kalpadakis, M Ximeri, ... Blood 134, 4913, 2019 | 4 | 2019 |
| EASIX is strongly associated with complement activation and overall survival in adult allogeneic hematopoietic cell transplantation recipients E Gavriilaki, I Sakellari, T Chatziconstantinou, D Mallouri, I Batsis, A Vardi, ... Blood 134, 4520, 2019 | 4 | 2019 |
| Caplacizumab for acquired thrombotic thrombocytopenic purpura: real-world multicenter data on re-administration and plasma exchange free treatment E Gavriilaki, E Koravou, S Dimou-Mpesikli, E Nikolousis, A Banti, ... Blood 140 (Supplement 1), 8503-8504, 2022 | 3 | 2022 |
| Transplant-associated Thrombotic Microangiopathy is Independently associated with Ruxolitinib Administration in Patients with graft-versus-hostdisease E Gavriilaki, I Sakellari, Z Bousiou, T Chatzikonstantinou, D Mallouri, ... BONE MARROW TRANSPLANTATION 55 (SUPPL 1), 332-332, 2020 | 3 | 2020 |
| Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data E Gavriilaki, E Nikolousis, EE Koravou, S Dimou-Besikli, C Kartsios, ... Frontiers in Medicine 10, 2023 | 2 | 2023 |
